(60 days)
The Boston Sight PD Prosthetic Device for daily wear is indicated for the management of a distorted corneal surface that:
- precludes satisfactory spectacle lens correction
- demonstrates significant improved rigid contact lens corrected vision
- is incapable of wearing traditional corneal lenses because of the inability to achieve adequate lens centration/stability and/or tolerance to physical contact with a lens
Causes of corneal distortion include corneal degeneration (e.g. keratoglobus, pellucid marginal degeneration, Salzmann's nodular degeneration), corneal dystrophy (e.g. lattice dystrophy, Reis-Bucklers dystrophy), and scarring from surgery (e.g. corneal transplant, LASIK, radial keratotomy), infection, or trauma.
The BostonSight PD Prosthetic Device for daily wear is also indicated for therapeutic use in eyes with ocular surface disease from dry eye (e.g. ocular Graft-versus-Host disease, Sjögren's syndrome, limbal stem cell deficiency (e.g.Stevens-Johnson syndrome, chemical and thermal burns, radiation), disorders of the skin (e.g. atopy, ectodermal dysplasia), neurotrophic keratitis (e.g. Herpes simplex, Herpes zoster, Familial Dysautonomia), and corneal exposure (e.g. anatomic, paralytic) that might benefit from the presence of an expanded tear reservoir and protection against an adverse environment. When prescribed for therapeutic use for distorted cornea or ocular surface disease, the BostonSight PD Prosthetic Device may incidentally provide correction of refractive error.
The BostonSight PD Prosthetic Device may be cleaned and disinfected using a chemical (not heat) care system.
The BostonSight PD Prosthetic Device is a daily wear, prosthetic device for the ocular surface lathe cut from one of the following fluoro-silicone acrylate materials:
- · roflufocon D (supplied by Contamac Ltd.)
- · roflufocon E (supplied by Contamac Ltd.)
- · oprifocon A (supplied by Bausch & Lomb, Inc.)
- · hexafocon B (supplied by Bausch & Lomb, Inc.)
The BostonSight PD Prosthetic Device is designed to vault over the cornea and rest on the conjunctiva overlying the sclera, resulting in a tear reservoir between the back surface of the prosthetic device and the corneal surface. The tear reservoir masks optical distortions from an irregular corneal surface, and in combination with the device itself, protects the ocular surface from an adverse external environment, including but not limited to dysfunctional evelids and margins. The design parameters are customized to allow for tear exchange underneath the device.
The BostonSight PD Prosthetic Device may be shipped "dry" or "wet" in a polypropylene contact lens case. The primary container for shipping the BostonSight PD Prosthetic Device is the Bausch & Lomb Frequent Replacement Contact Lens Case, with clearance under 510(k) K896685. When shipped "wet". The BostonSight PD Prosthetic Device manufactured from material supplied by Bausch & Lomb, inc. may be packaged and shipped in Boston Advance Comfort Formula Conditioning Solution (K974466) or Boston SIMPLUS Multi-Action solution (K024289). The BostonSight PD Prosthetic Device manufactured from material supplied by Contamac, Ltd. may be packaged and shipped "wet" in in the OPTIMUM by Lobob Cleaning and Disinfecting Storage solution, with clearance under 510(k) K014162.
This document is a 510(k) Summary of Safety and Effectiveness for the BostonSight PD Prosthetic Device, a rigid gas permeable contact lens. As such, it does not contain a study or data proving the device meets acceptance criteria. Instead, it asserts substantial equivalence to predicate devices based on device characteristics, indications for use, and a reliance on prior clearances for materials and clinical performance of similar devices.
Therefore, most of the requested information regarding acceptance criteria, sample sizes, expert involvement, and statistical analyses cannot be extracted from this document. However, I can provide the available information:
1. A table of acceptance criteria and the reported device performance
The document does not explicitly state acceptance criteria in a quantitative manner for performance. Instead, it relies on substantial equivalence to predicate devices, implying that if the new device is sufficiently similar to the legally marketed predicate devices, it is considered safe and effective. The table below summarizes the comparison to predicate devices, which implicitly defines the "performance" as being comparable in key design and material aspects.
| Characteristic | BostonSight PD Prosthetic Device (Subject Device) | BostonSight IC Corneal & Scleral Lens (K153066) (Predicate Device) | Boston® Scleral (itafluorofocon B) RGP Contact Lens (P860022/S40) (Predicate Device) |
|---|---|---|---|
| Indication for Use | Therapeutic use in eyes with ocular surface disease from dry eye, limbal stem cell deficiency, disorders of the skin, neurotrophic keratitis, and corneal exposure. May incidentally correct refractive error. | Correction of refractive error in aphakic and non-aphakic persons. For management of irregular corneal conditions (keratoconus, pellucid marginal degeneration, post-keratoplasty or LASIK). | Significantly reduced vision due to distorted corneal surface: 1. precludes satisfactory spectacle lens correction 2. demonstrates significantly improved RGP contact lens corrected vision 3. incapable of wearing traditional corneal lenses Also for ocular surface disorders benefiting from physical protection and saline bath. |
| Device Classification | Class II, Lenses, Rigid Gas Permeable, Daily Wear, HQD | Class II, Lenses, Rigid Gas Permeable, Daily Wear, HQD | Class II, Lenses, Rigid Gas Permeable, Daily Wear, HQD |
| Production Method | Lathe-cut | Lathe-cut | Lathe-cut |
| FDA Group # | Group # 3 Fluoro Silicone Acrylate | Group # 3 Fluoro Silicone Acrylate | Group # 3 Fluoro Silicone Acrylate |
| Water Content | <1% | <1% | <1% |
| UV Absorber/Blocker | YES | YES | YES |
| Materials | roflufocon D, roflufocon E, oprifocon A, hexafocon B | (Implied similar types, as it's the primary predicate for materials, but not explicitly listed in this table.) | itafiuorofocon B |
| Physical Properties | (Specific Dk, refractive index, etc. are listed for each material on page 6, considered comparable to predicates.) | (Not detailed in this summary table, but assessed in K153066 which is referenced) | (Not detailed in this summary table, but assessed in P860022/S40 which is referenced) |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
This document does not describe a new study with a test set. Instead, it relies on prior clearances for predicate devices and materials. Therefore, no information on sample size for a test set or data provenance is available here.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable, as no new study with a test set requiring ground truth establishment is described in this submission.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This device is a contact lens, not an AI-assisted diagnostic tool.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
Not applicable.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
Not applicable, as no new study with a test set requiring ground truth establishment is described in this submission. The "ground truth" for contact lens performance and safety is typically established through clinical trials submitted for PMA devices or through extensive post-market experience for predicate devices.
8. The sample size for the training set
Not applicable, as no new clinical study with a training set is described.
9. How the ground truth for the training set was established
Not applicable.
Summary based on the provided document:
The BostonSight PD Prosthetic Device gained 510(k) clearance by asserting substantial equivalence to existing legally marketed predicate devices. The "study" proving it meets acceptance criteria is primarily an analysis of its characteristics (materials, design, intended use) compared to previously cleared devices.
Specifically, the submission cross-references:
- Non-clinical studies and part of the clinical assessment: BostonSight IC Corneal & Scleral Lens (K153066).
- Therapeutic indications for use and device design: Boston® Scleral (itafluorofocon B) RGP Contact Lens (P860022/S40).
- Clinical studies for specific materials:
The document specifies that the new device does not raise different questions of safety and effectiveness than the identified predicate devices. Therefore, direct "acceptance criteria" and "device performance" in the context of a new, standalone study (as is often the case for AI/diagnostic devices) are not presented.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with the profiles overlapping to create a sense of depth and connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 25, 2016
BostonSight % Mr. Bret Andre Principal Consultant EyeReg Consulting, Inc. 6119 Canter Ln. West Linn, OR 97068
Re: K161461
Trade/Device Name: BostonSight PD Prosthetic Device Regulation Number: 21 CFR 886.5916 Regulation Name: Rigid Gas Permeable Contact Lens Regulatory Class: Class II Product Code: HOD Dated: May 20, 2016 Received: May 26, 2016
Dear Mr. Andre:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Denise L. Hampton -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K161461
Device Name BostonSight PD Prosthetic Device
Indications for Use (Describe)
The Boston Sight PD Prosthetic Device for daily wear is indicated for the management of a distorted corneal surface that:
-
- precludes satisfactory spectacle lens correction
-
- demonstrates significant improved rigid contact lens corrected vision
- is incapable of wearing traditional corneal lenses because of the inability to achieve adequate lens centration/stability and/or tolerance to physical contact with a lens
Causes of corneal distortion include corneal degeneration (e.g. keratoglobus, pellucid marginal degeneration, Salzmann's nodular degeneration), corneal dystrophy (e.g. lattice dystrophy, Reis-Bucklers dystrophy), and scarring from surgery (e.g. corneal transplant, LASIK, radial keratotomy), infection, or trauma.
The BostonSight PD Prosthetic Device for daily wear is also indicated for therapeutic use in eyes with ocular surface disease from dry eye (e.g. ocular Graft-versus-Host disease, Sjögren's syndrome, limbal stem cell deficiency (e.g.Stevens-Johnson syndrome, chemical and thermal burns, radiation), disorders of the skin (e.g. atopy, ectodermal dysplasia), neurotrophic keratitis (e.g. Herpes simplex, Herpes zoster, Familial Dysautonomia), and corneal exposure (e.g. anatomic, paralytic) that might benefit from the presence of an expanded tear reservoir and protection against an adverse environment. When prescribed for therapeutic use for distorted cornea or ocular surface disease, the BostonSight PD Prosthetic Device may incidentally provide correction of refractive error.
The BostonSight PD Prosthetic Device may be cleaned and disinfected using a chemical (not heat) care system.
| Type of Use (Select one or both, as applicable) |
|---|
| Prescription Use (Part 21 CFR 801 Subpart D) |
| Over-The-Counter Use (21 CFR 801 Subpart C) |
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
{3}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{4}------------------------------------------------
510 (k) SUMMARY OF SAFETY AND EFFECTIVENESS
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K161461 Applicant information: July 22nd, 2016 Date Prepared: Name: BostonSight Address 464 Hillside Avenue, Suite 205 Needham, MA 02494 Contact Person: Gene P. Guselli President and CEO Phone number: 781-726-7337 EyeReg Consulting, Inc. Consultant/Correspondent: Bret Andre Phone number (503) 372-5226 Fax number (503) 419-4475
Device Information:
| Device Classification: | Class II |
|---|---|
| Classification Number: | HQD |
| Classification Name: | Lenses, Rigid Gas Permeable, Daily Wear |
| Trade Name: | BostonSight PD Prosthetic Device |
{5}------------------------------------------------
Predicate Devices:
The BostonSight PD Prosthetic Device is substantially equivalent to the following predicate device(s)
- "BostonSight IC Corneal & Scleral Lens" . - Primary Predicate Manufactured by Boston Foundation for Sight 510(k) number; K153066
- "Boston" Scleral (itafluorofocon B) RGP Contact Lens for Daily Wear" . – Reference Predicate Manufactured by Boston Foundation for Sight PMA number: P860022/S40
Device Description:
The BostonSight PD Prosthetic Device is a daily wear, prosthetic device for the ocular surface lathe cut from one of the following fluoro-silicone acrylate materials:
- · roflufocon D (supplied by Contamac Ltd.)
- · roflufocon E (supplied by Contamac Ltd.)
- · oprifocon A (supplied by Bausch & Lomb, Inc.)
- · hexafocon B (supplied by Bausch & Lomb, Inc.)
The BostonSight PD Prosthetic Device is designed to vault over the cornea and rest on the conjunctiva overlying the sclera, resulting in a tear reservoir between the back surface of the prosthetic device and the corneal surface. The tear reservoir masks optical distortions from an irregular corneal surface, and in combination with the device itself, protects the ocular surface from an adverse external environment, including but not limited to dysfunctional evelids and margins. The design parameters are customized to allow for tear exchange underneath the device.
The BostonSight PD Prosthetic Device may be shipped "dry" or "wet" in a polypropylene contact lens case. The primary container for shipping the BostonSight PD Prosthetic Device is the Bausch & Lomb Frequent Replacement Contact Lens Case, with clearance under 510(k) K896685. When shipped "wet". The BostonSight PD Prosthetic Device manufactured from material supplied by Bausch & Lomb, inc. may be packaged and shipped in Boston Advance Comfort Formula Conditioning Solution (K974466) or Boston SIMPLUS Multi-Action solution (K024289). The BostonSight PD Prosthetic Device manufactured from material supplied by Contamac, Ltd. may be packaged and shipped "wet" in in the OPTIMUM by Lobob Cleaning and Disinfecting Storage solution, with clearance under 510(k) K014162.
{6}------------------------------------------------
| ROFLUFOCON D | ROFLUFOCON E | OPRIFOCON A | HEXAFOCON B | |
|---|---|---|---|---|
| Refractive Index | 1.4333 | 1.4332 | 1.4230 | 1.4240 |
| Light Transmission(clear) | >97% | >97% | >95% | >95% |
| Light Transmission(tinted) | >90% | >90% | >90% | >83% |
| Water Content | <1% | <1% | <1% | <1% |
| Dynamic ContactAngle (Receding) | 3° | 6° | 56° | 40° |
| Specific Gravity | 1.166 | 1.155 | 1.24 | 1.19 |
| Modulus | 697 MPa | 77 MPa | 1300 MPa | 1160 MPa |
| Shore D Hardness | 75 | 77 | 81 | 78 |
| OxygenPermeability(Dk)ISO/FATT Method | $100 x 10^{-11}$(cm2/sec) (ml O2/ml xmm Hg @ 35°C) | $125 x 10^{-11}$(cm2/sec) (ml O2/ml xmm Hg @ 35°C) | $85 x 10^{-11}$ (cm2/sec)(ml O2/ml x mm Hg @35°C) | $141 x 10^{-11}$(cm2/sec) (ml O2/ml xmm Hg @ 35°C) |
| contain one or moreof the followingcolor additivesconforming to:21 CFR Part 73 &74, Subpart D | D & C Green No.6, FD & C RedNo. 17,CI SolventYellow 18 | D & C Green No.6, FD & C RedNo. 17,CI SolventYellow 18 | D&C Green No.6and D&C YellowNo.10 | D&C Green No.6; C.I. SolventYellow No. 18;D&C Violet No.2; D&C Red No.17; C.I. SolventYellow No.18 |
| UV Light Blocking(UVB - 280nm –315nm; UVA 316nm- 380nm) | >98% UVB>95% UVA | >98% UVB>95% UVA | >95% UVB>97% UVA | >95% UVB>97% UVA |
The physical properties of the BostonSight PD Prosthetic Device manufactured from the various materials are as follows:
The parameters for the BostonSight PD Prosthetic Device are as follows:
- ન્ન્સ Chord Diameter:
- 米 Center Thickness:
- 米 Base Curve:
- 米 Spherical Powers:
18.0 mm to 26.0 mm 0.05mm to 0.60 mm 5.0 mm to 9.0 mm -25.00 Diopters to +35.00 Diopters
Indication for Use:
The Boston Sight PD Prosthetic Device for daily wear is indicated for therapeutic use for the management of a distorted corneal surface that:
-
- precludes satisfactory spectacle lens correction
-
- demonstrates significant improved rigid contact lens corrected vision
-
- is incapable of wearing traditional corneal lenses because of the inability to achieve adequate lens centration/stability and/or tolerance to physical contact with a lens
Causes of corneal distortion include corneal degeneration (e.g. keratoconus, keratoglobus, pellucid marginal degeneration, Salzmann's nodular degeneration), corneal dystrophy (e.g, lattice dystrophy, Reis-Bucklers dystrophy), and scarring from surgery (e.g. corneal transplant, LASIK, radial keratotomy), infection, or trauma.
{7}------------------------------------------------
The BostonSight PD Prosthetic Device for daily wear is also indicated for therapeutic use in eyes with ocular surface disease from dry eye (e.g. ocular Graft-versus-Host disease, Sjögren's syndrome, dry eye syndrome), limbal stem cell deficiency (e.g.Stevens-Johnson syndrome, chemical and thermal burns, radiation), disorders of the skin (e.g. atopy, ectodermal dysplasia), neurotrophic keratitis (e.g. Herpes simplex, Herpes zoster, Familial Dysautonomia), and corneal exposure (e.g. anatomic, paralytic) that might benefit from the presence of an expanded tear reservoir and protection against an adverse environment. When prescribed for therapeutic use for distorted cornea or ocular surface disease, the BostonSight PD Prosthetic Device may incidentally provide correction of refractive error.
The BostonSight PD Prosthetic Device may be cleaned and disinfected using a chemical (not heat) care system.
Description of Safety:
- ~ Non-Clinical Studies ~
Non-clinical testing to demonstrate the safety and effectiveness of contact lenses manufactured from roflufocon D, roflufocon E, oprifocon A, and hexafocon B has been addressed by reference to the predicate device, BostonSight IC Corneal & Scleral Lens (K153066).
~ Clinical Studies ~
Clinical testing to demonstrate the safety and effectiveness of contact lenses manufactured from roflufocon D, roflufocon E, oprifocon A, and hexafocon B has been addressed by reference to the following:
- OPTIMUM GP(roflufocon D, roflufocon E) Daily Wear Contact Lenses K033594 ●
- . Boston EQUALENS II (oprifocon A) Rigid Gas Permeable Contact Lenses - K022128
- . Boston XO2 (hexafocon B) Daily Wear Contact Lens - K071266
Substantial Equivalence:
The BostonSight PD Prosthetic Device is substantially equivalent to the Boston" Scleral (itafluorofocon B) RGP Contact Lens for Daily Wear (predicate device) in the following key areas:
- · Device Design
- · Therapeutic indications for use
The BostonSight PD Prosthetic Device is substantially equivalent to the BostonSight IC Corneal & Scleral Lens (predicate device) in the following key areas:
- Components/Materials/Formulation
- · Manufacturing Process
- Manufacturing Facility
- Final Packaging & Wet Shipping
{8}------------------------------------------------
The BostonSight PD Prosthetic Device is substantially equivalent to the predicate device as depicted in the following table, and does not raise different questions of safety and effectiveness than the predicate device identified previously.
The following table depicts the pre-clinical characteristics of the BostonSight PD Prosthetic Device, as well as the predicate device(s).
| BostonSight PD ProstheticDeviceSubject Device | BostonSight IC Corneal& Scleral Lens(K153066)Predicate Device | Boston® Scleral(itafluorofocon B)RGP Contact Lens(P860022/S40)Predicate Device | |
|---|---|---|---|
| Indication for Use | Indicated for therapeutic use in eyes withocular surface disease from dry eye (e.g.ocular Graft-versus-Host disease,Sjögren's syndrome, dry eye syndrome),limbal stem cell deficiency (e.g.Stevens-Johnson syndrome, chemical and thermalburns, radiation), disorders of the skin(e.g. atopy, ectodermal dysplasia),neurotrophic keratitis (e.g. Herpessimplex, Herpes zoster, FamilialDysautonomia), and corneal exposure(e.g. anatomic, paralytic) that mightbenefit from the presence of an expandedtear reservoir and protection against anadverse environment. When prescribedfor therapeutic use for distorted cornea orocular surface disease, the BostonSightPD Prosthetic Device may incidentallyprovide correction of refractive error. | Indicated for the correction ofrefractive error in aphakic and notaphakic persons. The lenses maybe prescribed in otherwise non-diseased eyes that require a rigidgas permeable lens for themanagement of irregular cornealconditions such as keratoconus,pellucid marginal degeneration orfollowing penetrating keratoplastyor refractive (e.g. LASIK)surgery. | Indicated for eyes havingsignificantly reduced visiondue to the presence of adistorted corneal surface that:1) precludes satisfactoryspectacle lens correction 2)demonstrates significantlyimproved rigid contact lenscorrected vision 3) isincapable of wearingtraditional corneal lensesbecause of the inability toachieve adequate lenscentration/stability and/ortolerance to physical contactwith a lens. Furthermore,eyes suffering from certainocular surface disorders maybenefit from the physicalprotection and the saline bathprovided by a scleral lens. |
| Device andClassification | Class IILenses, Rigid Gas Permeable, DailyWearHQD | Class IILenses, Rigid Gas Permeable,Daily WearHQD | Class IILenses, Rigid GasPermeable, Daily WearHQD(reclassified from Class IIto Class II in 1994) |
| Production Method | Lathe-cut | Lathe-cut | Lathe-cut |
| FDA Group # | Group # 3 Fluoro Silicone Acrylate | Group # 3 Fluoro SiliconeAcrylate | Group # 3 Fluoro SiliconeAcrylate |
| Water Content | <1% | <1% | <1% |
| UV Absorber/Blockeravailable | YES | YES | YES |
§ 886.5916 Rigid gas permeable contact lens.
(a)
Identification. A rigid gas permeable contact lens is a device intended to be worn directly against the cornea of the eye to correct vision conditions. The device is made of various materials, such as cellulose acetate butyrate, polyacrylate-silicone, or silicone elastomers, whose main polymer molecules generally do not absorb or attract water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.